1
|
Badano MN, Duarte A, Salamone G, Sabbione F, Pereson M, Chuit R, Baré P. Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children. Immunology 2023. [PMID: 37188378 DOI: 10.1111/imm.13656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Accepted: 04/25/2023] [Indexed: 05/17/2023] Open
Affiliation(s)
- María Noel Badano
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina
- Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Alejandra Duarte
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Gabriela Salamone
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Florencia Sabbione
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Matias Pereson
- Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Roberto Chuit
- Instituto de Investigaciones Epidemiológicas (IIE), Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Patricia Baré
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina
- Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires, Argentina
| |
Collapse
|
2
|
Badano MN, Pereson MJ, Sabbione F, Keitelman I, Aloisi N, Chuit R, de Bracco MME, Fink S, Baré P. SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies. Vaccines (Basel) 2023; 11:vaccines11030534. [PMID: 36992118 DOI: 10.3390/vaccines11030534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 02/16/2023] [Accepted: 02/21/2023] [Indexed: 03/31/2023] Open
Abstract
SARS-CoV-2 breakthrough infections, associated with waning immunity, increase systemic antibody levels. In this study, we analyzed the impact of the infection timing on the magnitude of the systemic humoral response and whether breakthrough infections also boost antibody levels in the salivary compartment. We observed that the combination of infection plus vaccination, regardless of infection timing, produced a sharp increase in systemic antibodies, which were higher in subjects infected after third doses. Moreover, despite high systemic antibody levels, breakthrough infections after dose three occurred and boosted antibody levels in the salivary compartment. These results suggest that current vaccination strategies against COVID-19 should be improved. Results also showed that determination of salivary antibodies against SARS-CoV-2 could be a valuable tool in disease prevalence studies, for the follow-up of vaccinated individuals, and to assist vaccination strategies against COVID-19, especially in settings where blood sampling cannot be fulfilled.
Collapse
Affiliation(s)
- María Noel Badano
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
- Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
| | - Matias J Pereson
- Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina
| | - Florencia Sabbione
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
| | - Irene Keitelman
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
| | - Natalia Aloisi
- Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
| | - Roberto Chuit
- Instituto de Investigaciones Epidemiológicas (IIE), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
| | - María M E de Bracco
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
| | - Susana Fink
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
| | - Patricia Baré
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
- Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, Buenos Aires 1425, Argentina
| |
Collapse
|
3
|
Erra L, Uriarte I, Colado A, Paolini MV, Seminario G, Fernández JB, Tau L, Bernatowiez J, Moreira I, Vishnopolska S, Rumbo M, Cassarino C, Vijoditz G, López AL, Curciarello R, Rodríguez D, Rizzo G, Ferreyra M, Ferreyra Mufarregue LR, Badano MN, Pérez Millán MI, Quiroga MF, Baré P, Ibañez I, Pozner R, Borge M, Docena G, Bezrodnik L, Almejun MB. COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity. J Clin Immunol 2023; 43:271-285. [PMID: 36251205 PMCID: PMC9574808 DOI: 10.1007/s10875-022-01382-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Accepted: 10/05/2022] [Indexed: 02/07/2023]
Abstract
Patients with inborn errors of immunity (IEI) in Argentina were encouraged to receive licensed Sputnik, AstraZeneca, Sinopharm, Moderna, and Pfizer vaccines, even though most of the data of humoral and cellular responses combination on available vaccines comes from trials conducted in healthy individuals. We aimed to evaluate the safety and immunogenicity of the different vaccines in IEI patients in Argentina. The study cohort included adults and pediatric IEI patients (n = 118) and age-matched healthy controls (HC) (n = 37). B cell response was evaluated by measuring IgG anti-spike/receptor binding domain (S/RBD) and anti-nucleocapsid(N) antibodies by ELISA. Neutralization antibodies were also assessed with an alpha-S protein-expressing pseudo-virus assay. The T cell response was analyzed by IFN-γ secretion on S- or N-stimulated PBMC by ELISPOT and the frequency of S-specific circulating T follicular-helper cells (TFH) was evaluated by flow cytometry.No moderate/severe vaccine-associated adverse events were observed. Anti-S/RBD titers showed significant differences in both pediatric and adult IEI patients versus the age-matched HC cohort (p < 0.05). Neutralizing antibodies were also significantly lower in the patient cohort than in age-matched HC (p < 0.01). Positive S-specific IFN-γ response was observed in 84.5% of IEI patients and 82.1% presented S-specific TFH cells. Moderna vaccines, which were mainly administered in the pediatric population, elicited a stronger humoral response in IEI patients, both in antibody titer and neutralization capacity, but the cellular immune response was similar between vaccine platforms. No difference in humoral response was observed between vaccinated patients with and without previous SARS-CoV-2 infection.In conclusion, COVID-19 vaccines showed safety in IEI patients and, although immunogenicity was lower than HC, they showed specific anti-S/RBD IgG, neutralizing antibody titers, and T cell-dependent cellular immunity with IFN-γ secreting cells. These findings may guide the recommendation for a vaccination with all the available vaccines in IEI patients to prevent COVID-19 disease.
Collapse
Affiliation(s)
- Lorenzo Erra
- Departamento de Fisiología, Biología Molecular y Celular, Instituto de Biociencias, Biotecnología y Biología Traslacional (IB3) e Instituto de Química Biológica (IQUIBICEN), FCEN, UBA, CONICET, Buenos Aires, CABA, Argentina
| | - Ignacio Uriarte
- Escuela Superior de Medicina, Universidad Nacional Mar del Plata-Hospital Interzonal Especializado Materno Infantil Don Vitorio Tetamanti, Mar del Plata, Buenos Aires, Argentina
| | - Ana Colado
- Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina, Buenos Aires, CABA, Argentina
| | | | | | - Julieta Belén Fernández
- Departamento de Fisiología, Biología Molecular y Celular, Instituto de Biociencias, Biotecnología y Biología Traslacional (IB3) e Instituto de Química Biológica (IQUIBICEN), FCEN, UBA, CONICET, Buenos Aires, CABA, Argentina
| | - Lorena Tau
- Laboratorio de Salud Pública de La Facultad de Ciencias Exactas, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), UNLP, CONICET, Asociado a CIC PBA, UNLP, La Plata, Argentina
| | - Juliana Bernatowiez
- Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina, Buenos Aires, CABA, Argentina
| | - Ileana Moreira
- Centro de Inmunología Clínica, Buenos Aires, CABA, Argentina
| | - Sebastián Vishnopolska
- Departamento de Fisiología, Biología Molecular y Celular, Instituto de Biociencias, Biotecnología y Biología Traslacional (IB3) e Instituto de Química Biológica (IQUIBICEN), FCEN, UBA, CONICET, Buenos Aires, CABA, Argentina
| | - Martín Rumbo
- Laboratorio de Salud Pública de La Facultad de Ciencias Exactas, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), UNLP, CONICET, Asociado a CIC PBA, UNLP, La Plata, Argentina
| | - Chiara Cassarino
- Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina, Buenos Aires, CABA, Argentina
| | - Gustavo Vijoditz
- Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina
| | - Ana Laura López
- Hospital General de Agudos C. G. Durand, Buenos Aires, CABA, Argentina
| | - Renata Curciarello
- Laboratorio de Salud Pública de La Facultad de Ciencias Exactas, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), UNLP, CONICET, Asociado a CIC PBA, UNLP, La Plata, Argentina
| | - Diego Rodríguez
- Escuela Superior de Medicina, Universidad Nacional Mar del Plata-Hospital Interzonal Especializado Materno Infantil Don Vitorio Tetamanti, Mar del Plata, Buenos Aires, Argentina
| | - Gastón Rizzo
- Laboratorio de Salud Pública de La Facultad de Ciencias Exactas, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), UNLP, CONICET, Asociado a CIC PBA, UNLP, La Plata, Argentina
| | - Malena Ferreyra
- Laboratorio de Salud Pública de La Facultad de Ciencias Exactas, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), UNLP, CONICET, Asociado a CIC PBA, UNLP, La Plata, Argentina
| | | | - María Noel Badano
- Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina, Buenos Aires, CABA, Argentina
| | - María Inés Pérez Millán
- Departamento de Fisiología, Biología Molecular y Celular, Instituto de Biociencias, Biotecnología y Biología Traslacional (IB3) e Instituto de Química Biológica (IQUIBICEN), FCEN, UBA, CONICET, Buenos Aires, CABA, Argentina
| | - María Florencia Quiroga
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Buenos Aires, CABA, Argentina
| | - Patricia Baré
- Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina, Buenos Aires, CABA, Argentina
| | - Itatí Ibañez
- Instituto de Química Física de los Materiales, Medio Ambiente y Energía (INQUIMAE), CONICET, FCEN, UBA, Buenos Aires, CABA, Argentina
| | - Roberto Pozner
- Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina, Buenos Aires, CABA, Argentina
| | - Mercedes Borge
- Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina, Buenos Aires, CABA, Argentina
| | - Guillermo Docena
- Laboratorio de Salud Pública de La Facultad de Ciencias Exactas, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), UNLP, CONICET, Asociado a CIC PBA, UNLP, La Plata, Argentina
| | | | - María Belén Almejun
- Departamento de Fisiología, Biología Molecular y Celular, Instituto de Biociencias, Biotecnología y Biología Traslacional (IB3) e Instituto de Química Biológica (IQUIBICEN), FCEN, UBA, CONICET, Buenos Aires, CABA, Argentina.
- Pabellón II, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Intendente Güiraldes 2160-Ciudad Universitaria-CABA C1428EG, Buenos Aires, Argentina.
| |
Collapse
|
4
|
Pereson MJ, Neukam K, Amaya L, Bare P, Echegoyen N, Badano MN, Lucero A, Martelli A, Garcia GH, Videla C, Martínez AP, Di Lello FA. 'Heterologous Gam-COVID-Vac (Sputnik V) / mRNA-1273 (Moderna) vaccination' - Author's reply. Clin Microbiol Infect 2022; 28:1514-1515. [PMID: 35724868 PMCID: PMC9212580 DOI: 10.1016/j.cmi.2022.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 06/11/2022] [Indexed: 11/12/2022]
Affiliation(s)
- Matías J Pereson
- Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM). Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Karin Neukam
- Servicio de Enfermedades Infecciosas, UCEIMP. Hospital Universitario Virgen del Rocío. Seville, Spain; Instituto de Biomedicina de Sevilla/CSIC/Universidad de Sevilla. Seville, Spain
| | - Lucas Amaya
- Servicio de Enfermedades Infecciosas, UCEIMP. Hospital Universitario Virgen del Rocío. Seville, Spain
| | - Patricia Bare
- Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina, Ciudad Autónoma de Buenos Aires, Argentina
| | - Natalia Echegoyen
- Virology Section, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno "CEMIC". Buenos Aires, Argentina
| | - María Noel Badano
- Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina, Ciudad Autónoma de Buenos Aires, Argentina
| | - Alicia Lucero
- Virology Section, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno "CEMIC". Buenos Aires, Argentina
| | - Antonella Martelli
- Virology Section, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno "CEMIC". Buenos Aires, Argentina
| | - Gabriel H Garcia
- Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM). Buenos Aires, Argentina
| | - Cristina Videla
- Virology Section, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno "CEMIC". Buenos Aires, Argentina
| | - Alfredo P Martínez
- Virology Section, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno "CEMIC". Buenos Aires, Argentina
| | - Federico A Di Lello
- Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM). Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina.
| |
Collapse
|
5
|
Urueña A, Badano MN, Baré P, González J, Vicentín R, Calli R, Cañero-Velasco MC, Fink S, Vizzotti C. Humoral and cellular immune memory response 12 years following single dose vaccination against hepatitis A in Argentinian children. Vaccine 2022; 40:114-121. [PMID: 34838323 DOI: 10.1016/j.vaccine.2021.11.037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 11/07/2021] [Accepted: 11/11/2021] [Indexed: 01/01/2023]
Abstract
Infants' universal hepatitis A virus (HAV) single-dose vaccination has been highly effective for controlling HAV infection in Argentina, and in other Latin-American countries that adopted that strategy. Although antibodies wane over time, this has not been associated with HAV outbreaks or breakthrough infections, suggesting a relevant role for memory immunity. This study assessed long term humoral and cellular immune memory response after an average of 12 years follow-up of HAV single-dose vaccination. We selected 81 HAV-single dose vaccinated individuals from a 2015 study, including 54 with unprotective (UAL) and 27 with protective antibody levels (PAL) against HAV. Humoral memory response was assessed by measuring anti-HAV antibody titers at admission in both groups, and 30 days after a booster dose in the UAL group. Flow cytometry analysis of peripheral blood mononuclear cell samples stimulated with HAV antigen was performed in 47/81 individuals (21 with PAL, 26 with UAL) to identify activated CD4 + memory T cells or CD8 + memory T cells. The results showed that 48/52 (92%) individuals from UAL group who completed follow up reached protective levels after booster dose. In the PAL group, anti-HAV Abs waned in 2/27 (7%) individuals lacking seroprotection, while in 25/27 (93%) Abs remained >10 mUI/mL. HAV-specific memory CD4 + T cells were detected in 25/47 (53.2%) subjects while HAV-specific memory CD8 + T cells were observed in 16/47 (34.04%) individuals. HAV-specific memory CD4+ and CD8+ T cell responses were detected in 11/21 (52.4%) and in 9/21 (42.9%) subjects with PAL and in 14/26 (53.8%) and in 7/26 (26.9%) individuals with UAL, showing that the presence of memory T-cells was independent of the level or presence of anti-HAV antibodies. Long-term immunity demonstrated in the present work, including or not antibody persistence, suggests that individuals with waned Ab titers may still be protected and supports the single-dose HAV strategy.
Collapse
Affiliation(s)
- A Urueña
- ISALUD University, Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Venezuela 931 C1095AAS, Ciudad Autónoma de Buenos Aires, Argentina.
| | - M N Badano
- Instituto de Medicina Experimental (IMEX)-CONICET. Academia Nacional de Medicina., Laboratorio de Patogenia de Infecciones Virales, Av. Gral. Las Heras 3092, C1425ASU Ciudad Autónoma de Buenos Aires, Argentina
| | - P Baré
- Instituto de Medicina Experimental (IMEX)-CONICET. Academia Nacional de Medicina., Laboratorio de Patogenia de Infecciones Virales, Av. Gral. Las Heras 3092, C1425ASU Ciudad Autónoma de Buenos Aires, Argentina
| | - J González
- INEI ANLIS "Dr. C. G. Malbrán", Laboratorio Nacional de Referencia para Hepatitis virales.Departamento Virología, Av. Vélez Sarsfield 601-637, C1282 AFG Ciudad Autónoma de Buenos Aires, Argentina
| | - R Vicentín
- Hospital de niños Orlando Alassia. Mendoza 4151, Ciudad de Santa Fe, Santa Fe, Argentina
| | - R Calli
- Dirección de Epidemiología, Ministerio de Salud Pública Provincia de Tucumán. 25 de Mayo 90, T4000 San Miguel de Tucumán, Tucumán, Argentina
| | - M C Cañero-Velasco
- Hospital Eva Perón de la Municipalidad de Merlo, Colón 502, Merlo, Provincia de Buenos Aires, Argentina
| | - S Fink
- Instituto de Medicina Experimental (IMEX)-CONICET. Academia Nacional de Medicina., Laboratorio de Patogenia de Infecciones Virales, Av. Gral. Las Heras 3092, C1425ASU Ciudad Autónoma de Buenos Aires, Argentina
| | - C Vizzotti
- ISALUD University, Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Venezuela 931 C1095AAS, Ciudad Autónoma de Buenos Aires, Argentina
| |
Collapse
|
6
|
Badano MN, Sabbione F, Keitelman I, Pereson M, Aloisi N, Colado A, Ramos MV, Ortiz Wilczyñski JM, Pozner RG, Castillo L, Wigdorovitz G, E de Bracco MM, Fink S, Chuit R, Baré P. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. Mol Immunol 2022; 143:94-99. [PMID: 35091231 PMCID: PMC8761547 DOI: 10.1016/j.molimm.2022.01.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 01/07/2022] [Accepted: 01/14/2022] [Indexed: 01/05/2023]
Abstract
SARS-CoV-2-specific humoral response was analyzed over time in a group of healthcare workers with or without exposure to SARS-CoV-2, who underwent vaccination with BBIBP-CorV (Sinopharm) vaccine in Argentina. Seroconversion rates in unexposed subjects after the first and second doses were 40 % and 100 %, respectively, showing a significant increase in antibody concentrations from dose 1 to dose 2 (p < 0.0001). The highest antibody concentrations were found in younger subjects and women, remaining significantly associated in a multivariable linear regression model (p = 0.005). A single dose of the BBIBP-CorV vaccine induced a strong antibody response in individuals with prior SARS-CoV-2infection, while a second dose did not increase this response. A sharp increase in antibody concentrations was observed following SARS-CoV-2 infection in those participants who became infected after the first and second doses (p = 0.008). Individuals with SARS-CoV-2 exposure prior to vaccination showed significantly higher anti-spike IgG antibody levels, at all-time points, than those not exposed (p < 0.001). Higher antibody titers were induced by a single dose in previously SARS-CoV-2 infected individuals than those induced in naïve subjects by two doses of the vaccine (p < 0.0001). Three months after the second dose both groups showed a decline in antibody levels, being more abrupt in unexposed subjects. Overall, our results showed a trend towards lower antibody concentrations over time following BBIBP-CorV vaccination. Sex and age seem to influence the magnitude of the humoral response in unexposed subjects while the combination of exposure to SARS-CoV-2 plus vaccination, whatever the sequence of the events was, produced a sharp increase in antibody levels. Evaluation of the humoral responses over time and the analysis of the induction and persistence of memory B and T cell responses, are needed to assess long-term immune protection induced by BBIBP-CorV vaccine.
Collapse
Affiliation(s)
- María Noel Badano
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina; Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina.
| | - Florencia Sabbione
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Irene Keitelman
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Matias Pereson
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Natalia Aloisi
- Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Ana Colado
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - María Victoria Ramos
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Juan Manuel Ortiz Wilczyñski
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Roberto Gabriel Pozner
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Luis Castillo
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Georgina Wigdorovitz
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - María Marta E de Bracco
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Susana Fink
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Roberto Chuit
- Instituto de Investigaciones Epidemiológicas (IIE), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| | - Patricia Baré
- Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina; Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA, 1425, Buenos Aires, Argentina
| |
Collapse
|
7
|
Maglioco A, Machuca DG, Badano MN, Nannini P, Camerano GV, Costa H, Meiss R, Ruggiero RA, Giordano M, Dran GI. B cells inhibit the antitumor immunity against an established murine fibrosarcoma. Oncol Lett 2017; 13:3225-3232. [PMID: 28521429 DOI: 10.3892/ol.2017.5810] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2016] [Accepted: 06/27/2016] [Indexed: 12/19/2022] Open
Abstract
Despite the classic role of B cells in favoring the immune response, an inhibitory action of B lymphocytes in tumor immunity has emerged in certain studies. In methylcolanthrene-induced murine fibrosarcoma (MCC), the loss of immunogenicity and the establishment of tolerance are paralleled by systemic immune suppression and the appearance of B+IL-10+ cells in tumor-draining lymph nodes. The present study aimed to assess the role of the B+IL-10+ cell population in the immune evasion and tolerance induced by MCC through the depletion of B cells in mice at various times of tumor progression: Prior to or subsequent to tumor implantation. Tumor growth and immunological parameters were evaluated. B cell depletion prior to tumor inoculum enhanced tumor growth, initiating the onset of the tumor-induced systemic immune response; however, an increase in the T regulatory cells (Tregs) at the tumor-draining lymph node could account for tumor exacerbation. B cell depletion once the tumor was established resulted in decreased tumor growth and a delayed onset of tolerance. Additionally, B cell absence exacerbated T cell dependent-tumor rejection, reduced Tregs and increased cytotoxic CD8+ T cells. In vitro analysis showed a direct effect of B cells upon T cell proliferation. In conclusion, B cell depletion exerts opposite effects when performed prior to or subsequent to tumor implantation. In this initially immunogenic tumor, B cell absence would delay the establishment of immunological tolerance probably by unmasking a pre-existing antitumor response. The present findings elucidate the convenience of modulating B cells in the development of future and more effective immunotherapies against cancer.
Collapse
Affiliation(s)
- Andrea Maglioco
- Laboratory of Experimental Oncology, Institute of Experimental Medicine (IMEX), The National Scientific and Technical Research Council (CONICET), National Academy of Medicine, Buenos Aires C1425AUM, Argentina.,Center for Higher Studies in Social Sciences and Health (CAECIHS), Interamerican Open University (UAI), Buenos Aires C1270AAH, Argentina
| | - Damián G Machuca
- Laboratory of Experimental Oncology, Institute of Experimental Medicine (IMEX), The National Scientific and Technical Research Council (CONICET), National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| | - María Noel Badano
- Laboratory of Experimental Immunology, IMEX, CONICET, National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| | - Paula Nannini
- Laboratory of Cancer Immunology, IMEX, CONICET, National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| | - Gabriela V Camerano
- IMEX, CONICET, National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| | - Héctor Costa
- IMEX, CONICET, National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| | - Roberto Meiss
- Department of Pathology, Institute of Oncology Studies, National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| | - Raúl A Ruggiero
- Laboratory of Experimental Oncology, Institute of Experimental Medicine (IMEX), The National Scientific and Technical Research Council (CONICET), National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| | - Mirta Giordano
- Laboratory of Cancer Immunology, IMEX, CONICET, National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| | - Graciela I Dran
- Laboratory of Experimental Oncology, Institute of Experimental Medicine (IMEX), The National Scientific and Technical Research Council (CONICET), National Academy of Medicine, Buenos Aires C1425AUM, Argentina
| |
Collapse
|
8
|
Camicia G, Noel Badano M, Maglioco A, Cabrera G, Costa H, Piazzon I, Nepomnaschy I. [Increase of regulatory T cells in the lymph node of cathepsin L mutant mice]. Medicina (B Aires) 2011; 71:361-365. [PMID: 21893450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Abstract
Regulatory CD4+CD25+Foxp3+ T cells (Treg) have been implicated in different pathologies including cancer, infections and autoimmune diseases and in the rejection of allogeneic organ transplantation. Thus, modulation of Treg activity has a great potential in the treatment of these pathologies. Herein, we evaluated the influence of cathepsin L (CTSL) on Treg homeostasis. CTSL mutant mice (CTSLnkt/nkt) showed a decrease in the absolute number of thymic Treg cells. In contrast, the absolute number of lymph node Treg cells and their frequency within CD4+ cells were increased. The absence of CTSL activity in CD4+ T cells -and not in their environment- increased the proliferation rate of lymph node CD4+ T cells. Treg and T CD4+ conventional (CD4+CD25-Foxp3-) cells from mutant mice showed similar increases in their proliferative levels as compared with control mice, suggesting that although proliferation contributes to the increases in their number, the augmentation in the frequency of Treg cells is not only associated to increases in proliferation. Furthermore, the Treg apoptosis rate was not decreased in the lymph node of CTSLnkt/nkt mice. Taking into account that the daily CD4+ thymic production is diminished in mutant mice, our results suggest that peripheral Treg increases are probably not the result of increased thymic output and raise the possibility that a conversion to Treg phenotype would be favored in the CD4+ T cells peripheral pool of CTSL mutant mice.
Collapse
Affiliation(s)
- Gabriela Camicia
- Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina
| | | | | | | | | | | | | |
Collapse
|